Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: DrJerry who wrote (26854)	12/12/1998 6:41:00 AM
From: Henry Niman	Respond to of 32384

DrJerry, I need to look a bit deeper at CELG. They are focused on anti-angiogenesis which is an area that is competitive, but could be quite lucrative. CELG has received approval for Thalidimide for leprosy and it has additional applications, such as cancer. They had a deal with ENMD and I think that they have just reaquired the rights, so I would have to dig a bit deeper into the details. Sometimes getting back your rights can indicated a lack of interest by the licensing party, and in some cases the party relinquishing rights may simply be missing the boat (look at LLY giving AGPH back the rights to Viracept). LGND of course has a very broad pipeline because they target a huge class of molecules (hormone receptors/transcription factors) which impact most diseases (which is one of the reasons that they have so many alliances with large pharmas). Do you know who is allied with CELG?